BioSpace News Archive

Winners of the 36th International ARC Awards have been announcement. The 2021 annual report of Fosun International Limited won Gold Award in the “Traditional Annual Report” category of the 2022 International ARC Awards.

Glaucoma Research Foundation (GRF) will host the 12th Annual Glaucoma 360 New Horizons Forum on February 3rd at San Francisco’s iconic Westin St. Francis Hotel.

ExeGi Pharma LLC, a leader in the development of live biotherapeutic drugs and probiotics, announced today that the FDA has cleared its Investigational New Drug (IND) application for its biologic drug candidate, EXE-346.

BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab (Brand Name in the U.S.: LEQEMBI™).

Rakovina Therapeutics Inc., is pleased to announce a scientific presentation at the 6th Annual DDR Inhibitors Summit in Boston, MA.

Independence Blue Cross (Independence) today announced the launch of its Advanced Network for Gene-Based Therapeutics, which will be effective March 1, 2023.

In many ways, our intestines serve as the front gate between our bodies and the world around us. They help digest our food and absorb our medications. They send alarm signals when harmful bacteria, viruses, and allergens invade.

Kaiser Permanente, the nation’s largest integrated, nonprofit health care provider, is expanding its work to address the causes and health consequences of gun violence with a $25 million commitment to its recently established Center for Gun Violence Research and Education.

Psycheceutical Bioscience, Inc (“Psycheceutical” or the “Company”) (OTC: BWVI), a bioscience company dedicated to developing cutting-edge treatments for mental health, has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for the first ketamine topical intended for treating post-traumatic stress disorder (PTSD).

ResMed (NYSE: RMD, ASX: RMD) today announced ResMed’s board of directors has appointed chief executive officer Michael (“Mick”) Farrell as chair of the board, effective January 25, 2023.